drug · intermediate · partly written
Revusiran
Revusiran was a sugar-tagged siRNA against transthyretin for amyloid heart disease; its phase 3 trial was stopped early after more patients died on the drug than on placebo, and the cause was not found.
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
Revusiran targeted the same protein as patisiran, but for heart disease. ENDEAVOUR was stopped early: 18 of 140 treated patients died on treatment against 2 of 66 on placebo. Lowering of transthyretin was the same in those who died and those who lived. The investigators found no cause and say the drug cannot be excluded. 1
Reported, not yet replicated
The decisive trial more
ENDEAVOUR was a phase 3 trial in people with hereditary transthyretin amyloidosis with cardiomyopathy: 140 on 500 mg revusiran under the skin (daily for 5 days across a week, then weekly) and 66 on placebo. Co-primary end points were 6-minute walk distance and serum TTR reduction. The sponsor stopped dosing after a median of 6.71 months. Deaths on treatment were 18 (12.9%) versus 2 (3.0%). Read from the abstract; the full text was not re-opened for this record. 1
Reported, not yet replicated
How the programme ended more
On 5 October 2016 the company announced it would discontinue development. In its own account, the trigger was new-onset or worsening peripheral neuropathy reported in a phase 2 extension study; the independent data monitoring committee found no conclusive evidence of a drug-related neuropathy signal in ENDEAVOUR but concluded that the benefit-risk balance no longer supported dosing, and later review of unblinded data showed the mortality imbalance. This is the company's statement, not an independent account. 2
Reported, not yet replicated
What is known and what is not about why more
The deaths were mostly heart failure, the usual course of this disease. Those who died were more often 75 or older and had more advanced heart failure at baseline; but drug level and TTR lowering were similar between those who died and those who survived, and heart scans, heart biomarkers and hospitalisations did not show a drug effect. The authors found no clear causative mechanism. This is a safety signal without a mechanism, in a population dying of its disease, and it cannot be fully resolved. Patisiran has the same target, and the APOLLO abstract reports adverse events of similar overall incidence and type to placebo; the difference lies in population, molecule and delivery together, and the papers cannot separate these. 13
Reported, not yet replicated
Design details from the full text deep
The paper describes revusiran as an siRNA joined to a triantennary GalNAc ligand, a first-generation design prone to enzyme breakdown, hence the heavy early dosing schedule. These details come from our check of the full text and were not re-opened for this record. 1
Unverified: from our own report, source not opened
Where it is limited deep
The trial ended early, so planned statistical tests were not run and the comparison of deaths is descriptive. The abstract reports no deleterious effect on heart scans, heart markers or hospitalisation frequency, so the excess deaths came without earlier warning in those measures. 1
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Clinicaltrials gov pivotal
NCT02319005
Trial name
ENDEAVOUR
Mechanism
An siRNA against transthyretin mRNA, meant to cut the liver's production of the protein that forms amyloid in the heart. It was given as a subcutaneous injection: 500 mg daily for 5 days across a week, then weekly. The trial's co-primary end points were distance walked in 6 minutes and the reduction in serum TTR. 1
Reported, not yet replicated
Delivery route
Must survive
The siRNA has to survive blood and reach liver cells. The trial paper describes a GalNAc sugar tag that sends it to the liver and a first-generation chemistry that needed heavy early dosing; those details come from the full text, which was not re-opened for this record. 1
Unverified: from our own report, source not opened
Side effects
Deaths on treatment
18 of 140 patients (12.9 percent) on revusiran and 2 of 66 (3.0 percent) on placebo died during the on-treatment period. Most deaths in both arms were adjudicated as cardiovascular, from heart failure, consistent with the natural history of the disease. 1
Reported, not yet replicated
Liver, kidney and nerve events
Full-text figures relayed by our source check, not re-opened here: hepatic events 34.3 percent versus 13.6 percent, renal events 22.1 versus 10.6 percent, serious peripheral neuropathy 5.0 versus 0 percent. 1
Unverified: from our own report, source not opened
Verdict
Outcome
failed
Why
Dosing was stopped after a median of 6.71 months because of a mortality imbalance between the arms. The company announced on 5 October 2016 that it would discontinue development, after a data monitoring committee concluded that benefit and risk no longer supported dosing. Whether revusiran itself caused the excess deaths was not established. 12
Reported, not yet replicated
Failure mode
ENDEAVOUR randomised 206 patients 2:1 (140 revusiran, 66 placebo). The sponsor stopped dosing early. Deaths on treatment were 18 (12.9%) versus 2 (3.0%). A post hoc review found that the patients who died were more often 75 or older and had more advanced heart failure at baseline, but drug exposure and TTR lowering did not differ between those who died and those who lived, and echocardiographic parameters, cardiac biomarkers and the frequency of cardiovascular and heart failure hospitalisation were not made worse. The authors write that no clear causative mechanism could be identified and that a role for revusiran cannot be excluded. The cause is unknown. 12
Reported, not yet replicated
Teach this
In one sentence
Revusiran lowered its target as intended, but its trial was stopped when 18 of 140 treated patients died against 2 of 66 on placebo, and no one found why. 1
Reported, not yet replicated
The five-minute version
Revusiran was an siRNA against transthyretin for amyloid heart disease, injected under the skin. In ENDEAVOUR the sponsor stopped dosing early after a mortality imbalance. The post hoc review found older, sicker patients among those who died, but exposure and TTR lowering did not differ between those who died and those who survived, and no mechanism was identified. The authors cannot exclude a role for the drug. 1
Reported, not yet replicated
What a listener will ask
Did the drug fail to lower transthyretin?
No; TTR lowering did not differ between patients who died and those who lived, so target knockdown could not explain the outcome. 1
Reported, not yet replicated
So is RNAi unsafe?
Was the cause found later?
Not in the sources opened: the paper says no clear causative mechanism could be identified. 1
Reported, not yet replicated
The common wrong idea
If a drug hits its molecular target as designed, it must be working and safe.
Revusiran lowered TTR, and the lowering was the same in patients who died and who survived, yet the trial was stopped for deaths; hitting the target and helping patients are separate claims. 1
Reported, not yet replicated
The one citation to hand over: 1
Still open here
- What caused the mortality imbalance, or whether it was chance in a very sick population: the authors could not identify a mechanism.
- Whether the first-generation chemistry, the cumulative dose or the population explains it: no source opened tests this.
- The full text of the trial paper, including the neuropathy, liver and kidney tables, was not re-opened for this record.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Judge DP, et al.. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther (2020). paper; opened 2026-11-17 all records citing this
- Alnylam announces discontinuation of revusiran development (press release exhibit to an SEC filing, 5 October 2016). U.S. Securities and Exchange Commission (EDGAR), Alnylam Pharmaceuticals exhibit 99.1 (2016). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Adams D, et al.. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med (2018). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (6)
This record has been changed 6 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2016
- Regulatory status
- failed-in-trials
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/drugs/revusiran.json